MIT AI Algorithm Stabilizes RNA Vaccines for Heat Resistance

MIT researchers have engineered a heat-resistant formulation for RNA vaccines using artificial intelligence, overcoming the critical logistical barrier of ultracold storage. Led by principal investigator Ana Jaklenec and senior author Robert Langer at MIT's Koch Institute, the team developed a machine-learning algorithm to optimize lipid nanoparticles used to deliver mRNA. Published in Nature Biotechnology, the work demonstrates that vaccines can remain stable at room temperature for up to a year or at nearly 38 degrees Celsius for two months, while maintaining robust immunogenicity. The researchers collaborated with MIT's Computer Science and Artificial Intelligence Laboratory to create an algorithm capable of predicting optimal formulations from small datasets. By screening nearly 50 FDA-approved excipients, the AI rapidly identified effective stabilizers, reducing the experimental workload from months of trial-and-error to just a few weeks. Postdoc Khanh Tran noted the algorithm converged quickly, whereas previous attempts to stabilize FDA-approved lipid nanoparticle structures had stalled despite extensive prescreening. The optimized lipid nanoparticles, structurally similar to those used in Moderna and Pfizer vaccines, were tested by packaging COVID-19 mRNA antigens. After vacuum drying and storage at elevated temperatures, the vaccines elicited immune responses in mice equivalent to those produced by original cold-chain formulations. The team also successfully formulated solid microneedle patches containing the heat-stable antigen, which triggered comparable immune reactions, opening pathways for needle-free administration. The approach is versatile; the AI model successfully stabilized Pfizer-style lipid nanoparticles in addition to Moderna-like structures. Jaklenec emphasized that once a heat-resistant formulation is established for a specific lipid nanoparticle class, it can be adapted to deliver diverse mRNA payloads. This breakthrough facilitates wider global distribution of RNA therapeutics by eliminating reliance on complex cold storage and supports the development of advanced drug-delivery systems requiring solid-state stability.